Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: Mechanistic insights

Sorafenib, a multi-kinase inhibitor with antiangiogenic, antiproliferative, and proapoptotic properties, is the first-line treatment for patients with late-stage hepatocellular carcinoma (HCC). However, the therapeutic effect remains limited due to sorafenib resistance. Only about 30% of HCC patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Xinchen, Yan, Tinghao, Liu, Fen, Liu, Qingbin, Zhao, Jing, Xiong, Huabao, Jiang, Shulong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441942/
https://www.ncbi.nlm.nih.gov/pubmed/36071839
http://dx.doi.org/10.3389/fphar.2022.991052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441942/
https://www.ncbi.nlm.nih.gov/pubmed/36071839
http://dx.doi.org/10.3389/fphar.2022.991052

Ejemplares similares